Recombinant PD-1 antibody
Quick Overview for Recombinant PD-1 antibody (ABIN7828483)
Target
See all PD-1 (PDCD1) AntibodiesAntibody Type
Reactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Purpose
- Recombinant PD1 Monoclonal Antibody
-
Purification
- Protein A purified
-
Immunogen
- Synthetic peptide derived from the human PD1 protein
-
Isotype
- IgG, kappa
-
-
-
-
Application Notes
- IHC 1:200-1:1000,IF 1:50
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 1 mg/mL
-
Buffer
- PBS, 50 % glycerol, 0.05 % Proclin 300, 0.05 % protein protectant.
-
Preservative
- ProClin
-
Precaution of Use
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Storage
- -20 °C
-
Storage Comment
- Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.
-
Expiry Date
- 12 months
-
-
- PD-1 (PDCD1) (Programmed Cell Death 1 (PDCD1))
-
Alternative Name
- PD1
-
Background
- SLEB,hSLE,Programmed Death,programmed cell death,Programmed cell death protein,Systemic lupus erythematosus susceptibility,hPD,PDCD1,CD279,PD-1,PD1,SLEB2,hPD-1,hPD-l,hSLE1,programmed cell death 1,PD 1,CD279 antigen,hPD 1,hPD l,PDCD 1,Programmed cell death 1 protein,Programmed Death-1,Protein PD 1,Protein PD-1,Systemic lupus erythematosus susceptibility 2,Programmed cell death protein 1,CD279,CD279 antigen,hPD 1,hPD l,hPD-1,hSLE1,PD 1,PD-1,PD1,PDCD 1,PDCD1,PDCD1,Programmed cell death 1,Programmed cell death 1 protein,Programmed cell death protein 1,Protein PD 1,Protein PD-1,SLEB2,Systemic lupus erythematosus susceptibility 2,The programmed cell death 1 protein (PD1) is an inhibitory receptor expressed on antigen activated T-cells that plays a critical role in the induction and maintenance of immune tolerance to self-antigens. Upon binding to its ligands CD274/PDCD1L1 (PD-L1) and CD273/PDCD1LG2 (PD-L2), PD1 is phosphorylated within its immunoreceptor tyrosine-based switch motif (ITSM), which facilitates the recruitment of the protein tyrosine phosphatase PTPN11/SHP-2. PTPN11/SHP-2 then dephosphorylates key T-cell receptor (TCR) proximal signaling molecules, including ZAP70, PRKCQ/PKC theta and CD247/CD3 zeta, leading to the direct inhibition of T-cell activation. The PD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and evade destruction by the immune system, thereby facilitating tumor survival. Cat.No. Product Name Clone No. IF:{{item.impact}} Journal:{{item.journal}} ({{item.year}}) DOI:{{item.doi}} Reactivity:{{item.species}} Sample Type:{{item.sample_type}} Previous {{ page }} Next Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}} Previous {{ page }} Next [
-
UniProt
- Q15116
-
Pathways
- Cancer Immune Checkpoints
Target
-